

# ASX Announcement

## 14 May 2021

Cogstate Limited  
ABN 80 090 975 723

Suite 117  
425 Smith Street  
Fitzroy Victoria 3065  
Australia

P +61 3 9664 1300  
F +61 3 9664 1301  
W cogstate.com

## Option Issued Under Employee Share Option Plan

Cogstate (ASX.CGS) today announced the issue of options under the Employee Share Option Plan to key executives. The relevant Appendix 3G has also been lodged this same day.

### Issue of options to Financial Controller

Cogstate has appointed Mr Rohan Prentice as Financial Controller. Under the terms of employment with Mr Prentice, options have been issued under the Cogstate Employee Share Option Plan in three tranches as detailed below:

	Tranche 1	Tranche 2	Tranche 3
Number of options	100,000	100,000	50,000
Exercise Price	\$0.993 per share	\$0.993 per share	\$0.993 per share
Vesting Terms	Time based vesting	Time & Performance based vesting	Time & Performance based vesting
Performance Criteria	N/A	EBIT greater than US\$4m in any one of FY22, FY23 or FY24	EBIT greater than US\$7m collectively over FY22, FY23 or FY24
Vesting Date	<ul style="list-style-type: none"> <li>25,000 options vest on 28 Feb 2023</li> <li>75,000 options vest on 28 Feb 2024</li> </ul>	<ul style="list-style-type: none"> <li>25,000 options will vest on 28 Aug 2023</li> <li>75,000 options will vest on 28 Aug 2024</li> </ul>	<ul style="list-style-type: none"> <li>15,000 options will vest on 28 Aug 2023</li> <li>35,000 options will vest on 28 Aug 2024</li> </ul>
Expiry Date	28 Feb 2026	28 Aug 2026	28 Aug 2026

This announcement was authorised for release by a sub-committee of the Board of Directors of Cogstate Ltd.

---

**About Cogstate**

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 ([nouknow.jp](http://nouknow.jp)). For more information, please visit [www.cogstate.com](http://www.cogstate.com).

**For further information contact:**

David Franks, Company Secretary, [david.franks@atomicgroup.com.au](mailto:david.franks@atomicgroup.com.au)